-
CHITOSE and FUJIFILM Biosciences Form Strategic Alliance to Drive Global Innovation and Biopharmaceutical Manufacturing
-
High-Performance Novel HAT Cell Line for Gene Therapy, Published in Molecular Therapy Methods & Clinical Development, and Ready for Commercial Use
-
Name Update Announcement: “MATSURI Project” Becomes “MATSURI Initiative”
-
Paper on Novel CHO-MK Cell Line Receives 2025 Excellent Paper Award from the Society of Biotechnology, Japan
-
Chitose Laboratory Changes Head Office Location, Names the New Primary Operations Office “C3-Hub”
-
CHITOSE Group Announces Capital Increase of JPY 7.3 Billion Scale through Third-Party Allotment
